Please assess the completion status of the following clinical trial:

Trial Title: T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological proven advanced ovarian-, fallopian tube or primary peritoneal cancer with the possibility of surgical removal of tumor tissue of \> 1 cm3. All histologies can be included.~2. Progressive or recurrent resistant disease after platin-based chemotherapy (platinum resistant) or progressive or recurrent disease after second line or additional chemotherapy.~3. Age: 18 - 75 years.~4. ECOG performance status of ≤1 (Appendix 2).~5. Life expectancy of \> 6 months.~6. At least one measurable parameter in accordance with RECIST 1.1 -criteria.~7. LVEF assessment with documented LVEF ≥50% by either TTE or MUGA (TTE preferred test) within 6 months from first study drug administration~8. No significant toxicities or side effects (CTC ≤ 1) from previous treatments, except sensory- and motoric neuropathy (CTC ≤ 2) and/or alopecia (CTC ≤ 2).~9. Sufficient organ function, including:~   * Absolute neutrophil count (ANC) ≥ 1.500 /µl~  * Leucocyte count ≥ lower normal limit~  * Platelets ≥ 100.000 /µl and \<700.000 /µl~  * Hemoglobin ≥ 6,0 mmol/l (regardless of prior transfusion)~  * S-creatinine \< 140~  * S-bilirubin ≤ 1,5 times upper normal limit~  * ASAT/ALAT ≤ 2,5 times upper normal limit~  * Alkaline phosphatase ≤ 5 times upper normal limit~  * Lactate dehydrogenase ≤ 5 times upper normal limit~  * Sufficient coagulation: APPT\<40 and INR\<1,5~10. Signed statement of consent after receiving oral and written study information~11. Willingness to participate in the planned controls and capable of handling toxicities.~12. Age and Reproductive Status: Females, ages ≥18 years, inclusive~    * Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \[hCG\]) within 24 hours prior to the start of study treatment.Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception. This applies from inclusion in the study and for the duration of treatment with Ipilimumab, Relatlimab and Nivolumab plus 5 half-lives of study treatment plus 30 days (duration of ovulatory cycle) for a total of 24 weeks post-treatment completion. The following are considered safe methods of contraception:~   * Hormonal anticonception (birth control pills, spiral, depot injection with gestagen, subdermal implantation, hormonal vaginal ring and transdermal depot patch)~   * Intrauterine device~   * Surgical sterilization~   * Surgical sterilization of male partner with verification of no sperm after the procedure~   * Menopause (for more than 12 months)~Exclusion Criteria:~Patients will be excluded if they meet one of the criteria's listed below~1. A history of prior malignancies. Patients treated for another malignancy can participate if they are without signs of disease for a minimum of 3 years after treatment.~2. Known hypersensitivity to one of the active drugs or one or more of the excipients.~3. Severe medical conditions, such as severe asthma/COLD, significant cardiac disease, poorly regulated insulin dependent diabetes mellitus among others.~4. Creatinine clearance \< 70 ml/min (1).~5. Acute/chronic infection with HIV, hepatitis, syphilis among others.~6. Severe allergies or previous anaphylactic reactions.~7. Active autoimmune disease, such as autoimmune neutropenia/thrombocytopenia or hemolytic anemia, systemic lupus erythematosis, Sjögren's syndrome, sclerodermia, myasthenia gravis, Goodpasteur's disease, Addison's disease, Hashimotos thyroiditis, active Graves disease.~8. Subjects with history of myocarditis, regardless of etiology~9. Troponin T (TnT) or I (TnI) \> 2x institutional upper limit of normal (ULN) is excluded. ii) between \> 1 to 2 x ULN will be permitted if a repeat assessment remains ≤ 2 x ULN and participant undergoes a cardiac evaluation and is cleared by a cardiologist or cardio-oncologist~10. Prior treatment with LAG-3 targeted agents.~11. Pregnant women and women breastfeeding.~12. Simultaneous treatment with systemic immunosuppressive drugs (including prednisolone, methotrexate among others) (2).~13. Simultaneous treatment with other experimental drugs. Based on clinical judgement antihormonal treatment can be accepted.~14. Simultaneous treatment with other systemic anti-cancer treatments.~15. Patients with active and uncontrollable hypercalcemia~(1)In selected cases it can be decided to include a patient with a GFR \< 70 ml/min with the use of a reduced dose of chemotherapy.~(2)In selected cases a systemic dose of ≤10 mg prednisolone or a transient planned treatment that can be stopped before TIL therapy can be tolerated.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Without Ipilimumab (Type: OTHER): At Step 1, 6 patients will be treated without Ipilimumab pre tumor harvest. If feasible and tolerable, as defined by no additional SAE/SAR compared to the previously completed pilot studies at CCIT-DK, the trial will move to Step 2.~Depending on the safety and feasibility on step 2, 6 more patients can be included at step 1.
- With Ipilimumab (Type: OTHER): At Step 2, 6 patients will be included. Ipilimumab 3 mg/kg will be administered 2-6 weeks pre tumor harvest.~If no additional SAE/SAR compared to the previous completed pilot study at CCIT-DK is observed additional 6 patients can be included at Step 2. If on the other hand Step 2is not found safe additional 6 patients can be included at Step 1

Based on this trial design, predict the completion outcome and termination type (if applicable).